Dr. Hamid on Potential Combinations With Docetaxel in mHSPC Subtypes

Partner | Cancer Centers | <b>Dana Farber</b>

Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses potential combinations with docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC) subtypes.

Patients with luminal B mHSPC appear to benefit from docetaxel, says Hamid.

However, it is not yet understood whether the luminal B and basal subtypes respond similarly to available hormonal therapies such as abiraterone acetate (Zytiga), enzalutamide (Xtandi), and apalutamide (Erleada) as classic mHSPC, explains Hamid.

These agents are being investigated in prospective clinical trials for this patient population, says Hamid.

Additionally, the RNA profiling data from those studies may shed light on the utility of hormonal therapy in these subtypes of mHSPC, concludes Hamid.